Table 1.

Clinical Status and Sequences of GLP-1 Receptor Peptide Agonists

Peptide	Clinical Status	Sequence	Ref.
GLP-1 (7–36)		HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH2	[Lopez et al. 1983]
Exendin-4	Approved	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2	[Eng et al. 1992]
Liraglutide (Victoz, Saxenda)	Approved	HAEGTFTSDVSSYLEGQAA-(K-P1)-EFIAWLVRGRG	[Bayes et al. 2003; Ostawal et al. 2016]
Exenatide (Byetta, Bydureon)	Approved	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2	[Gedulin et al. 2003]
CJC-1131	Preclinical (No longer in development)	HaEGTFTSDVSSYLEGQAAKEFIAWLVKGR-P2	[Kim et al. 2003]
Albiglutide (Eperzan, Tanzeum)	Approved	HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGR-Albumin	[Stewart et al. 2008]
Taspoglutide	Failed Phase III (Hypersensitivity)	H-Aib-EGTFTSDVSSYLEGQAAKEFIAWLVK-Aib-R-NH2	[Sebokova et al. 2010]
CJC-1134	Canceled Phase II (Competition)	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPP-P3	[Baggio et al. 2008]
Lixisenatide	Approved	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2	[Christensen et al. 2009]
Exenatide-XTEN	Phase I	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-XTEN	[Schellenberger et al. 2009]
Efpeglenatide (LAPS CA Exendin-4, LAPS Exendin-4, HM11260C)	Phase II	4-imidazoacetyl-GEGTFTSDLSKQMEEEAVRLFIEWL-(K-PEG-Fc)-NGGPSSGAPPPS-NH2	[Choi et al. 2014]
Dulaglutide (Trulicity)	Approved	HGEGTFTSDVSSYLEEQAAKEFIAWLVKGG-Fc-Fc-GGKVLWAIFEKAAQEELYSSVDSTFTGEGH	[Jimenez-Solem et al. 2010]
Semaglutide (NN9924/OG217SC)	Phase III	H-Aib-EGTFTSDVSSYLEGQAA-(K-P4)-EFIAWLVRGRG-NH2	[Lund et al. 2011]
Amphiphile Mimetic	Preclinical	HSEGTFTSDGEEEAAVV-(K-P5)-NH2	[Khan et al. 2012]
Coumaglutide (13c)	Preclinical	HGEGTFTSDV-(C-P6)-SYLEGQAAKEFIAWLVKGR-NH2	[Sun et al. 2015b]
I-3	Preclinical	HGEGTFTSDLS-(C-P7)-QMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2	[Sun et al. 2016]

Text that is bolded indicates modification from the native GLP-1 (7-36 amide) sequence. See Fig. 2 for the chemical structures represented by pendant groups P1-7.